An experimental drug from GlaxoSmithKline Plc may one day give people a way to prevent HIV infection with an injection every three months instead of daily pills, raising the odds they’ll stick with the therapy.
Johnson & Johnson struck the first deal to license an experimental AIDS drug before regulatory approval, reigniting debate over how much companies should do to speed access to HIV treatments in poor countries.
The largest and most advanced study under way of a vaccine to prevent HIV infection was stopped by U.S. government researchers after an interim look at the data showed it was unlikely to help recipients.
The Obama administration boosted its pledge to the Global Fund to Fight AIDS, Tuberculosis & Malaria by 38 percent, to $4 billion, while urging changes to make the organization more efficient and more accountable.
The White House is poised to release the country’s first comprehensive domestic strategy against AIDS, as funds to prevent infections have failed to halt the epidemic in those most at risk of the disease, AIDS groups said.
A vaginal gel containing Gilead Sciences Inc. ’s AIDS drug Viread cut HIV infections by as much as 54 percent in a trial in South Africa, the first time such a product has protected women after six previous gels failed.
Deaths from AIDS continued to decline last year as the number of people on HIV drugs worldwide surged 21 percent from 2010, according to a report that found poor and middle income countries spent more on treatment.
Healthy people can protect themselves from the deadly HIV virus if they take Gilead Sciences Inc.’s Truvada every day. Whether patients will is an issue dividing AIDS advocates as U.S. regulators weigh approving the pill as the first preventative measure against the disease.
Millions of HIV infections could be averted by treating patients earlier than current guidelines recommend, after a study showed giving pills to patients as soon as they’re diagnosed can prevent them infecting others.